Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-05-10
2005-05-10
Weddington, Kevin E. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S023000, C514S365000
Reexamination Certificate
active
06890905
ABSTRACT:
The present invention discloses methods for therapeutically treating mammals, including but not limited to humans, to increase the relative insulin producing performance of endogenous pancreatic β-cells, to cause differentiation of pancreatic epithelial cells into insulin producing β-cells, to improve muscle sensitivity to insulin and other weight control efforts by the chronic oral administration of a DP IV-inhibitor. The administration causes the active form of GLP-1 and other non-nutrient stimulated growth hormones to remain biologically active longer under physiological conditions. The extended presence of such hormones, in particular in the pancreatic tissue can also facilitate differentiation and regeneration of the β-cells already present that are in need of repair.
REFERENCES:
patent: 2961377 (1960-11-01), Shapiro et al.
patent: 3174901 (1965-03-01), Sterne
patent: 3879541 (1975-04-01), Kabbe et al.
patent: 3960949 (1976-06-01), Ahrens et al.
patent: 4028402 (1977-06-01), Fischer et al.
patent: 4935493 (1990-06-01), Bachovchin et al.
patent: 5433955 (1995-07-01), Bredehorst et al.
patent: 5462928 (1995-10-01), Bachovchin et al.
patent: 5512549 (1996-04-01), Chen et al.
patent: 5543396 (1996-08-01), Powers et al.
patent: 5614379 (1997-03-01), MacKellar
patent: 5624894 (1997-04-01), Bodor
patent: 5939560 (1999-08-01), Jenkins et al.
patent: 6006753 (1999-12-01), Efendic
patent: 6011155 (2000-01-01), Villhauer
patent: 6107317 (2000-08-01), Villhauer
patent: 6110949 (2000-08-01), Villhauer
patent: 6124305 (2000-09-01), Villhauer
patent: 6172081 (2001-01-01), Damon
patent: 6303661 (2001-10-01), Demuth et al.
patent: 6319893 (2001-11-01), Demuth et al.
patent: 6500804 (2002-12-01), Demuth et al.
patent: DD 296 075 (1991-11-01), None
patent: 25 42 598 (1976-04-01), None
patent: 196 16 486 (1997-10-01), None
patent: 299 09 210 (1999-09-01), None
patent: 198 26 972 (1999-12-01), None
patent: 0 658 568 (1995-06-01), None
patent: 0 708 179 (1996-04-01), None
patent: 0 995 440 (2000-04-01), None
patent: 2 085 665 (1971-12-01), None
patent: 2 696 740 (1994-04-01), None
patent: 04-288098 (1992-10-01), None
patent: 4334357 (1992-11-01), None
patent: WO 9111457 (1991-08-01), None
patent: WO 9116339 (1991-10-01), None
patent: WO 9117767 (1991-11-01), None
patent: WO 9308259 (1993-04-01), None
patent: WO 9511689 (1995-05-01), None
patent: WO 9515309 (1995-06-01), None
patent: WO 9529691 (1995-11-01), None
patent: WO 9740832 (1997-11-01), None
patent: WO 9745117 (1997-12-01), None
patent: WO 9819998 (1998-05-01), None
patent: WO 9822494 (1998-05-01), None
patent: WO 9946272 (1999-09-01), None
patent: WO 9962914 (1999-12-01), None
patent: WO 0001849 (2000-01-01), None
patent: WO 0010549 (2000-03-01), None
patent: WO 0053171 (2000-09-01), None
patent: WO 0174299 (2000-10-01), None
patent: WO 0134594 (2001-05-01), None
patent: WO 0162266 (2001-08-01), None
patent: WO 0189569 (2001-11-01), None
patent: WO 0197808 (2001-12-01), None
patent: WO 0220825 (2002-03-01), None
Holst et al., “Inhibition of the Activity of Dipeptidyl-Peptidase IV as a Treatment for Type 2 Diabetes”, Diabetes (1998), 47(11), pp. 1663-1670.*
Campbell, I.W.New Antidiabetic Drugs,ed. C.J. Bailey & P.R. Flatt, Smith-Gordon, “Sulphonylureas and the metformin: efficacy and inadequacy”. 3:33-51 (1990).
The Merck Index, 11thEdition,An Encyclopedia of Chemicals, Drugs,and Biologicals, 1989, p. 934.
The Merck Index, 12thEdition,An Encyclopedia of Chemicals, Drugs,and Biologicals, 1996, p. 1014.
Martindale The Extra Pharmacopoeia,30thEdition, London Pharmaceutical Press, 1993, p. 1619.
Martindale The Extra Pharmacopoeia,30thEdition, London Pharmaceutical Press, 1993, p. 36.
Chemical Abstracts,vol. 115. No. 15, Oct. 14, 1991 Columbus, Ohio, US; abstract No. 149947q, Schoen Ekkehard et al: “Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes”.
Chemical Abstracts,vol. 126, No. 2, Jan. 13, 1997 Columbus, Ohio, US; abstract No. 16161j, Stoeckel A. et al.: “Competitive inhibition of proline specific enzymes by amino acid thioxopyrrolidides and thiazolidides”.
Chemical Abstracts,vol. 118, No. 25, Jun. 21, 1993 Columbus, Ohio, US; abstract No. 255342k, Hosoda, et al, “Preparation of N-(heterocyclic Carbonyl) Amino Acids and Analogs as Prolyl Endopeptidase Inhibitors”, (Nov. 29, 1992).
Arai et al., “Synthesis of prolyl endopeptidase inhibitors and evaluation of their structure-activity relationships: in vitro inhibition of prolyl endopeptidase from Canine Brain”Chemical and Pharmaceutical Bulletin,Bd. 41, No. 9, 1993, pp. 1583-1588.
J. Lin et al.: “Inhibition of depeptidyl peptidase IV by fluoroolefin-containing n-peptidyl-O-hydroxylamine peptidomimetics”Proceedings of the National Academy of Sciences of USA,vol. 95, Nov. 1998, pp. 14020-14024.
Korom, S., et al “Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients”,Transplantation,vol. 63, 1495-1500 No. 10 (1997).
Tanka, S., et al., “Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV”.Int. J. Immunopharmacol,vol. 19, No. 1, pp. 15-24, (1997).
Mentlein, R., et al., “Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV”.Regul. Pept.49, 133-144 (1993).
Wetzel, W., et al., “Effects of the CLIP fragment ACTH 20-24 on the duration of REM sleep episodes”.Neuropeptides,31, 41-45 (1997).
Amasheh, S., et al., “Electrophysiological analysis of the function of the mammalian renal peptide transporter expressed inXenopus laevisoocytes”.J. Physiol.504, 169-174 (1997).
Durinx, C.; et al.; “Reference Values for Plasma Dipeptidyl-Peptidase IV activity and their Association with Other Laboratory Parameters”.Clin Chem Lab Med 2001,Feb.; 39(2):155-9, 1 page.
Gossrau, R.; “Cytochemistry of Membrane Proteases”.Histochem J,Jul. 1985; 17 (7):737-71, 1 page.
Hahn, T.; et al.; “Enzyme Histochemical Evidence for the Presence of Potential Blood Pressure Regulating Proteases in Cultured Villous Explants from Human First Trimester Placentae”.Acta HistochemDec., 1993, 95 (2):185-92, 1 page.
Heymann, E. et al., “Has Dipeptidyl Peptidase IV an Effect on Blood Pressure and Coagulation.”Klin Wochenschr,Jan. 2, 1984;62 (1):2-10, 1 page.
Magyar, C.E. et al., “Proximal Tubule Na Transporter Responses are the same during Acute and Chronic Hypertension.”Am J. Physiol Renal Physiol,Aug., 2000; 279 (2):F358-69, 1 page.
Papies, B. et al., “Isoenzyme (Lactate Dehydrogenase, Aspartate Aminotransferase) and Dipeptidyl Peptidase IV Activity Changes in Blood Plasma Likely Indicative of Organ Involvement due to Arterial Hypertension.”Cor Vasa,1991; 33(3):218-26, 1 page.
Qureshi. N.U.; et al., “Endogenous Neuropeptide Y Mediates Vasoconstriction during Endotoxic and Hemorrhagic Shock”.Regul Pept,Sep. 25, 1998; 75-76:215-20, 1 page.
Index Nominum,International Drug Directory 1992/1993,Medpharm Scientific Publishers, pp. 728-729.
The Merck Index,An Encyclopedia of Chemicals and Drugs,9thEdition, Merck & Co., Inc., 1976, p. 773.
Willms et al.,Journal of Clinical Endocrinology Metabolism,“Gastric Emptying, Glucose Responses, and Insulin Secretion after a Liquid Test Meal: Effects of Exogenous Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide in Type 2 (Noninsulin-Dependent) Diabetic Patients”, 1996, 81(1): 327-332.
Hoffmann et al.,Journal of Chromatography A,“Inhibition of dipeptidyl peptidase IV (DP IV) by anti-DP IV antibodies and non-substrate X-X-Pro- oligopeptides ascertained by capillary electrophoresis”, 1995, 716:355-362.
C.B. Welch,Medical Management of Non-Insulin-Dependent (Type II) Diabetes,3rdedition, American Diabetes Association, “Diagnosis and Classification” p. 3, 1994, Pharmacologic
Demuth Hans-Ulrich
Glund Konrad
Kuehn-Wache Kerstin
Pospisilik Andrew J.
Brown, Rudnick, Berlack & Israels, LLP.
Prosidion Limited
Weddington Kevin E.
LandOfFree
Methods for improving islet signaling in diabetes mellitus... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for improving islet signaling in diabetes mellitus..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for improving islet signaling in diabetes mellitus... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3452422